Skip to main content

Prognosis and End Results

  • Chapter
Lung Tumors

Part of the book series: UICC Current Treatment of Cancer ((1360))

Abstract

As detailed previously surgery offers the only major prospect of cure in non-small cell lung cancer. Of all patients presenting with this disease only 25% undergo thoracotomy following staging and, on average, about 5% of these subjects will still be unresectable despite a negative mediastinoscopy. This is almost always due to nodal involvement beyond the range of the mediastinoscope or tumor invading vital structures in the mediastinum. Thus about 20% of all patients will undergo a curative resection of which 4%–5% will be alive and tumor free at 5 years — a 25% 5-year survival rate overall for this selected group of resected patients (Fig.l). The other 15% of patients will die of local or distant recurrence within 5 years. The overall 5-year survival figure of 20%–30% and 10-year survival of 16%–18% (there is a significant falloff between 5 and 10 years due to metastatic spread from slowly growing lung cancers) has not changed during the last 30 years. These figures can, however, be somewhat misleading as they include 40%–50% of patients with stage I disease. In stage I disease the 2-year survival when staging was originally looked at by Mountain et al. in 1974 was 47% for squamous cell carcinoma (see Table 1).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Further Reading

  • Huhti E, Sutinen S, Saloheimo M (1981) Survival among patients with lung cancer: an epidemio-logical study. Am Rev Respir Dis 124: 13–16

    PubMed  CAS  Google Scholar 

  • Hyde L, Yee J, Wilson R, Patno ME (1965) Cell type and the natural history of lung cancer. JAMA 193: 52

    Article  PubMed  CAS  Google Scholar 

  • Martini N, Beatie EJ (1977) Results of surgical treatment in stage I lung cancer. J Thorac Cardio-vasc Surg 74: 499–507

    CAS  Google Scholar 

  • Mountain CR (1977) Assessment of the role of surgery for control of lung cancer. Am Thorax Surg 24: 365–373

    Article  CAS  Google Scholar 

  • Mountain CF, Carr DT, Anderson WAD (1974) A system for the clinical staging of lung cancer. Am J Roentgenol Radium Ther Nucl Med 120: 130–138

    PubMed  CAS  Google Scholar 

  • Roswitt B, Patno ME, Rapp R, Veinburgs A, Feder B, Stuhlbarg J, Reid CB (1968) The survival of patients with inoperable lung cancer: a large scale randomized study of radiation therapy versus placebo. Radiology 90: 688–697

    Google Scholar 

Download references

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 1988 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Spiro, S.G. (1988). Prognosis and End Results. In: Hoogstraten, B., Addis, B.J., Hansen, H.H., Martini, N., Spiro, S.G. (eds) Lung Tumors. UICC Current Treatment of Cancer. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-82873-7_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-82873-7_13

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-16920-8

  • Online ISBN: 978-3-642-82873-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics